Shenzhen Hengkaifeng's Sensitivity Toothpastes listing was inaccurate, making the drug misbranded, FDA says.
What happened
FDA reviewed the firm’s electronic drug listing for Sensitivity Toothpastes (NDC 84117-013) and found the listed active ingredient was hydrated silica, while the label lists potassium nitrate 5% and sodium fluoride 0.1%. FDA also found the listing said liquid and oral, while the label says foam for dental administration. FDA had sent listing deficiency and data removal notices before this letter.
What FDA found
The listing did not give the correct active ingredient names and quantities, because it listed hydrated silica while the label lists potassium nitrate 5% and sodium fluoride 0.1%.
21 CFR 207.49(a)(4)The listing did not give the correct dosage form and route of administration, because it listed liquid and oral while the label says foam for dental administration.
21 CFR 207.49(a)(6) & (11)FDA says the firm did not meet its drug listing obligations.
section 510(j) of the FD&C Act, 21 U.S.C. 360(j); section 301(p), 21 U.S.C. 331(p)FDA says the product is misbranded because it is not properly listed with FDA.
section 502(o) of the FD&C Act, 21 U.S.C. 352(o)FDA says introducing or delivering the misbranded drug into interstate commerce is prohibited.
section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
What FDA wants
FDA asks the firm to notify it in writing within 15 working days of receipt of the specific steps taken to correct the violations, including explanations and supporting documents; if corrective actions cannot be completed, the firm must state why and give a timeframe.
Who should pay attention
- companies responsible for NDC drug listings
- distributors or sellers of foreign-made drug products
- regulatory staff handling eDRLS listing data
This is a summary. Read the original letter on fda.gov.